Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2014 17:17 ET | Source: Novavax, Inc.

U.S. FDA Grants Fast Track Designation to Novavax' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M(TM)

GAITHERSBURG, Md., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
October 27, 2014 07:30 ET | Source: Novavax, Inc.

Novavax Announces Ebola Vaccine Development Program at the 8th Vaccine and ISV Conference in Philadelphia

First Ebola Vaccine Candidate based on the 2014 Guinea Ebola Strain Genetic Sequence Robust immune responses demonstrated in preclinical studies; exceptional responses when used with Novavax'...
October 26, 2014 10:00 ET | Source: Novavax, Inc.

Novavax Presents RSV F Protein Nanoparticle Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26

GAITHERSBURG, Md., Oct. 26, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
October 23, 2014 16:15 ET | Source: Novavax, Inc.

Novavax to Present RSV Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26

GAITHERSBURG, Md., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
October 15, 2014 08:30 ET | Source: Novavax, Inc.

Novavax Study Published in Vaccine: RSV F-Protein Nanoparticle Vaccine Induces Antigenic Site II Antibodies

Vaccinated Animals Generated a Broad Spectrum of Protective Antibodies Vaccine Induces Antibodies that are at Least as Protective as Palivizumab Palivizumab Competing Antibody Response...
October 14, 2014 08:30 ET | Source: Novavax, Inc.

Novavax Initiates Phase 2 Clinical Trial of RSV Vaccine in Elderly Subjects

GAITHERSBURG, Md., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
September 23, 2014 08:45 ET | Source: Novavax, Inc.

Novavax Announces BARDA Exercise of Contract Option

Award of Option Period for 24 months Additional Option Period Funding Commitment of $70 million Clinical, Manufacturing and Product Development Activities Funded Up to Phase...
September 23, 2014 08:30 ET | Source: Novavax, Inc.

Novavax' H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM) Delivers Positive Phase 1/2 Clinical Data

Vaccine and adjuvant were well-tolerated, consistent with the company's prior studies with saponin-based adjuvants Hemagglutination-inhibiting antibody responses similar to prior Novavax...
September 16, 2014 16:05 ET | Source: Novavax, Inc.

Novavax Initiates Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine Candidate in Healthy Third-Trimester Pregnant Women

GAITHERSBURG, Md., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...
September 11, 2014 16:56 ET | Source: Novavax, Inc.

Novavax to Host 2nd Annual Analyst and Investor Meeting

GAITHERSBURG, Md., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant...